Study of 611 for children with moderate to severe eczema
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests a new medicine called 611 for children with moderate to severe eczema (atopic dermatitis). It aims to see if 611 can reduce eczema symptoms and improve quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 2 and 12 years old and weigh at least 15 kg.
- Eczema must have been present for at least 3 to 6 months (depending on age)
- Eczema must cover at least 10% of the body surface area and be scored as moderate to severe.
- Your child must have tried topical treatments (like creams) without enough improvement.
- You must be willing to apply moisturizer twice a day throughout the study.
- Your child must not have certain infections, cancers, or other serious health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injectable medicine (611) for teenagers with moderate to severe eczema that hasn't been helped enough by creams. It aims to see if the drug can safely reduce itching and skin symptoms.
This study tests a new medication called IBI3002 for people with moderate to severe eczema (atopic dermatitis) that hasn't been well controlled by standard creams. The goal is to see if IBI3002 can reduce skin inflammation and itching.
This study tests a new medicine called CMS-D001 for adults with moderate to severe eczema (atopic dermatitis) that hasn't improved enough with standard creams. Participants will receive either CMS-D001 or a placebo to see if it helps reduce itching and skin symptoms.
This trial tests a new treatment called CM512 for people with moderate-to-severe eczema (atopic dermatitis). It aims to see if the drug can improve skin symptoms like itching and rash.
This study compares two versions of an experimental drug called 611 to see how they work in the body. It's for healthy volunteers to help find the best formulation for future treatments.
This study tests two new study medicines (PF-07275315 and PF-07264660) for people with moderate to severe eczema that hasn't responded well to other treatments, including biologics. The goal is to see if these medicines can help reduce itching and clear the skin.
Hear when a new Dermatitis, Atopic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.